MacuSight has initiated a phase I study of its proprietary formulation of sirolimus to evaluate its safety and efficacy as a treatment for wet age-related macular degeneration (AMD).
MacuSight has initiated a phase I study of its proprietary formulation of sirolimus to evaluate its safety and efficacy as a treatment for wet age-related macular degeneration (AMD).
The randomized, open-label, dose escalation trial will enrol 30 patients to receive a single injection of sirolimus. There are to be six treatment arms with patients receiving one of three doses of the formulation via a subconjunctival injection or one of three doses via intravitreal injection.
Sirolimus is a broad-acting compound that is able to combat disease through multiple mechanisms of action including anti-angiogenesis, immunosuppression, anti-migration, anti-proliferation, anti-fibrosis and anti-permeability.
MacuSight recently initiated a similar phase I trial of the formulation in patients with diabetic macular oedema.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.